+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Endometrial Cancer Treatment Market by Treatment Type, Drug Class, Line of Therapy, Mode of Administration, Administration Setting - Global Forecast to 2030- Product Image
Endometrial Cancer Treatment Market by Treatment Type, Drug Class, Line of Therapy, Mode of Administration, Administration Setting - Global Forecast to 2030- Product Image
Sale

Endometrial Cancer Treatment Market by Treatment Type, Drug Class, Line of Therapy, Mode of Administration, Administration Setting - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888365
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Endometrial Cancer Treatment Market grew from USD 8.87 billion in 2024 to USD 9.38 billion in 2025. It is expected to continue growing at a CAGR of 5.50%, reaching USD 12.24 billion by 2030.

A New Era in Endometrial Cancer Care

Endometrial cancer represents a growing clinical and economic challenge, driven by demographic shifts, evolving risk factors, and breakthroughs in therapeutic science. Over the past decade, the treatment paradigm has shifted from a narrow focus on surgery and conventional chemotherapy to an integrated approach that incorporates targeted agents, immunotherapies, and precision medicine strategies. This executive summary distills the key forces reshaping the landscape and offers a concise yet thorough overview of emerging trends, regulatory changes, and market segmentation dynamics that every stakeholder must understand.

By synthesizing qualitative insights from leading oncologists, payers, and patient advocates with rigorous secondary research, this summary provides a clear window into the critical factors influencing decision-making in this rapidly evolving field. From the impact of novel drug classes to regional variances in access and reimbursement, readers will gain a holistic view of the endometrial cancer treatment ecosystem. This introduction sets the stage for a deep dive into transformative shifts, tariff implications, segmentation nuances, regional variances, company strategies, and actionable recommendations designed to inform strategic planning and investment priorities.

Defining Shifts Transforming Therapeutic Approaches

Recent years have marked a profound transformation in endometrial cancer treatment, characterized by the integration of precision oncology and immune modulation into standard care pathways. Advances in molecular diagnostics now enable clinicians to stratify patients based on genomic profiles, unlocking the potential of mTOR inhibitors and PARP inhibitors to target specific tumor vulnerabilities. Meanwhile, the arrival of immune checkpoint inhibitors targeting CTLA-4 and PD-1 has introduced new avenues for durable responses in advanced disease stages, challenging the traditional reliance solely on surgery and chemotherapy.

This shifting therapeutic paradigm is further supported by combination regimens that synergize novel agents with established chemotherapies or hormonal therapies. As combination therapy protocols gain traction, multidisciplinary care teams are collaborating more closely to optimize sequencing and dosing schedules. In parallel, technological innovations in drug delivery and biomarker development are accelerating the translation of early-stage research into clinical practice. Collectively, these advancements are setting the stage for more personalized, effective, and tolerable treatment options that promise to improve outcomes across diverse patient populations.

Assessing the Ripple Effects of 2025 US Tariffs

The implementation of newly announced US tariffs in 2025 has introduced a complex layer of cost considerations into the endometrial cancer treatment supply chain. Increased duties on imported active pharmaceutical ingredients and oncology drug components have exerted upward pressure on production costs, prompting manufacturers to re-evaluate sourcing strategies and supplier relationships. In response, several leading innovators have begun diversifying their procurement to include domestic and low-tariff regions, thereby mitigating exposure to trade policy fluctuations.

These financial headwinds have also influenced pricing negotiations with payers and hospital systems, with some providers seeking formulary adjustments or volume-based rebates to maintain budget neutrality. At the same time, ambitious R&D programs are reassessing resource allocation to balance the pursuit of next-generation targeted agents against the reality of compressed margins. While the long-term effects of these tariff changes remain to be fully realized, early indicators suggest a trend toward strategic reshoring, enhanced supply chain transparency, and collaborative cost-sharing agreements between manufacturers and healthcare systems.

Unveiling Critical Segmentation Perspectives

Delving into treatment type illustrates that chemotherapy, while still fundamental, shares the stage with combination therapy protocols that pair chemotherapeutic backbones with hormonal agents and immunomodulators. Hormone therapy continues to play a critical role, particularly in early-stage and maintenance settings, though immunotherapy’s rapid ascent signals a major redefinition of standard regimens. Radiation therapy and surgical interventions remain indispensable, yet targeted therapy’s rise underscores a shift toward precision interventions guided by biomarker status.

When examined through the lens of drug class, the landscape reveals robust growth in antiangiogenic therapies that disrupt tumor vascularization. Chemotherapeutic agents, notably platinum-based compounds and taxanes, retain a central role across multiple lines of care. Hormonal agents such as aromatase inhibitors and progestins support a significant segment of maintenance strategies, while immune checkpoint inhibitors directed at CTLA-4 and PD-1 receptors open new frontiers for durable responses. Precision therapies, including mTOR inhibitors, PARP inhibitors, and tyrosine kinase inhibitors, further enrich the armamentarium with targeted approaches that minimize off-target toxicities.

A line of therapy perspective exposes distinct patterns of treatment sequencing, with first-line protocols increasingly incorporating targeted or immunotherapeutic elements, and later lines emphasizing combination regimens to overcome resistance. Mode of administration insights highlight a growing preference for oral formulations that enhance patient adherence and quality of life, although intravenous delivery remains critical for select high-potency agents and combination strategies. Finally, the distribution of treatment settings showcases the evolution of care delivery, with ambulatory care centers expanding capacity for outpatient infusions and hospital inpatient and outpatient services adapting to the integration of novel procedures and monitoring requirements.

Navigating Regional Dynamics in Global Markets

Regional analysis reveals a mosaic of market characteristics shaped by healthcare infrastructure, reimbursement frameworks, and epidemiological trends. In the Americas, a combination of strong payer support and well-established oncology networks facilitates rapid uptake of next-generation therapies, though reimbursement negotiations can slow market entry for high-cost agents. Meanwhile, Europe, the Middle East & Africa presents a heterogeneous environment in which regulatory harmonization in Europe accelerates access, but economic disparities and variable healthcare budgets across the Middle East and Africa create pockets of limited availability and demand tailored affordability solutions.

Across Asia-Pacific, rising incidence rates driven by lifestyle shifts intersect with governments’ expanding investment in cancer care. Major economies are fostering domestic manufacturing and clinical trial infrastructure to support both global and local innovation. Efforts to streamline regulatory pathways and introduce outcome-based pricing models underline a commitment to balancing cost and access. As these regions continue their distinct trajectories, stakeholders must remain attuned to evolving policy landscapes, infrastructure investments, and patient advocacy movements that will define the next generation of market expansion opportunities.

Spotlight on Leading Therapeutic Innovators

Leading biopharmaceutical companies are doubling down on pipeline assets that address unmet needs in endometrial cancer, with several late-stage trials evaluating novel immunotherapy combinations alongside targeted inhibitors. Partnerships between pharmaceutical innovators and biotech firms are accelerating the translation of cutting-edge science, especially in the development of companion diagnostics that enable patient selection and monitor treatment response. Collaborative alliances with academic centers are also enhancing the robustness of clinical evidence, while strategic acquisitions are consolidating portfolios with complementary mechanisms of action.

Simultaneously, emerging players are carving out niches by advancing differentiated technologies, such as next-generation sequencing platforms, patient-reported outcome tools, and data analytics platforms that support real-world evidence generation. Established oncology leaders are leveraging their global commercial infrastructure to accelerate launch strategies, whereas smaller organizations capitalize on agility to navigate evolving regulatory landscapes. Across the spectrum, companies that blend scientific innovation with robust stakeholder engagement and adaptive market access strategies are best positioned to lead the next wave of therapeutic breakthroughs.

Strategic Actions for Industry Advancement

Industry leaders should prioritize the development of integrated treatment pathways that combine precision diagnostics with tailored therapeutic regimens, ensuring that molecular insights directly inform patient care. Robust partnerships between drug developers, diagnostic providers, and healthcare systems will be critical to streamline patient identification and optimize resource utilization. Additionally, advancing real-world evidence initiatives can bolster payer confidence, support value-based contracting, and facilitate differentiated pricing strategies aligned with demonstrated outcomes.

To navigate the evolving tariff environment, organizations must diversify supply chain footprints, engage proactively with policymakers, and explore collaborative cost-sharing frameworks that mitigate pricing pressures. Expansion into high-growth regional markets demands a nuanced approach that balances global best practices with locally relevant access models. By investing in digital health tools that support telemedicine and decentralized clinical trials, companies can enhance patient engagement, accelerate study enrollment, and gather granular data to inform continuous refinement of treatment algorithms.

Robust Methodology Underpinning Our Insights

This analysis is grounded in a rigorous research framework that combines comprehensive secondary research with targeted primary interviews. Extensive peer-reviewed literature, regulatory filings, clinical trial registries, and financial statements provided the foundational data, while in-depth discussions with oncologists, policy experts, payers, and patient representatives yielded qualitative insights into evolving practices and unmet needs.

Data triangulation ensured alignment across multiple sources, and advanced analytical tools were employed to identify thematic patterns, regional differentials, and competitive dynamics. Key findings underwent validation through expert panels to confirm relevance, accuracy, and applicability. This methodological approach ensures that the insights presented here reflect the latest advancements and strategic imperatives within endometrial cancer treatment, offering stakeholders a reliable basis for informed decision-making.

Concluding Insights on Future Trajectories

As the endometrial cancer treatment landscape continues to evolve, stakeholders must remain agile and informed. The convergence of molecular diagnostics, immunotherapy, and targeted agents presents unprecedented opportunities, yet also demands strategic foresight to address cost pressures, regulatory shifts, and regional disparities. By synthesizing segmentation insights with regional trends and company strategies, organizations can craft differentiated value propositions that resonate with payers, providers, and patients alike.

Ultimately, success in this dynamic environment will hinge on collaboration-linking scientific innovation with adaptive market access models and patient-centered care delivery. This executive summary has illuminated the critical forces at play and offered a blueprint for charting the path forward. As new data emerge and policy landscapes shift, maintaining a proactive stance will be essential to unlocking the full potential of the next generation of endometrial cancer therapies.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Chemotherapy
    • Combination Therapy
    • Hormone Therapy
    • Immunotherapy
    • Radiation Therapy
    • Surgery
    • Targeted Therapy
  • Drug Class
    • Antiangiogenic Therapy
    • Chemotherapeutic Agents
      • Platinum Based Agents
      • Taxanes
    • Hormonal Therapy
      • Aromatase Inhibitors
      • Progestins
    • Immunotherapy
      • CTLA-4 Inhibitors
      • PD-1 Inhibitors
    • Targeted Therapy
      • MTOR Inhibitors
      • PARP Inhibitors
      • Tyrosine Kinase Inhibitors
  • Line Of Therapy
    • First Line
    • Fourth Line And Beyond
    • Second Line
    • Third Line
  • Mode Of Administration
    • Intravenous
    • Oral
  • Administration Setting
    • Ambulatory Care
    • Hospital Inpatient
    • Hospital Outpatient
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • Eli Lilly and Company

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Endometrial Cancer Treatment Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.3. Combination Therapy
8.4. Hormone Therapy
8.5. Immunotherapy
8.6. Radiation Therapy
8.7. Surgery
8.8. Targeted Therapy
9. Endometrial Cancer Treatment Market, by Drug Class
9.1. Introduction
9.2. Antiangiogenic Therapy
9.3. Chemotherapeutic Agents
9.3.1. Platinum Based Agents
9.3.2. Taxanes
9.4. Hormonal Therapy
9.4.1. Aromatase Inhibitors
9.4.2. Progestins
9.5. Immunotherapy
9.5.1. CTLA-4 Inhibitors
9.5.2. PD-1 Inhibitors
9.6. Targeted Therapy
9.6.1. MTOR Inhibitors
9.6.2. PARP Inhibitors
9.6.3. Tyrosine Kinase Inhibitors
10. Endometrial Cancer Treatment Market, by Line of Therapy
10.1. Introduction
10.2. First Line
10.3. Fourth Line and Beyond
10.4. Second Line
10.5. Third Line
11. Endometrial Cancer Treatment Market, by Mode of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
12. Endometrial Cancer Treatment Market, by Administration Setting
12.1. Introduction
12.2. Ambulatory Care
12.3. Hospital Inpatient
12.4. Hospital Outpatient
13. Americas Endometrial Cancer Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Endometrial Cancer Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Endometrial Cancer Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. GlaxoSmithKline plc
16.3.3. Eisai Co., Ltd.
16.3.4. Bristol-Myers Squibb Company
16.3.5. F. Hoffmann-La Roche Ltd
16.3.6. AstraZeneca PLC
16.3.7. Pfizer Inc.
16.3.8. Novartis AG
16.3.9. Johnson & Johnson
16.3.10. Eli Lilly and Company
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ENDOMETRIAL CANCER TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. ENDOMETRIAL CANCER TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. ENDOMETRIAL CANCER TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ENDOMETRIAL CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 68. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 69. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 70. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 71. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 72. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 74. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 78. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 120. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 123. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 124. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 125. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 126. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 127. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 129. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 130. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 132. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 133. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 134. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 135. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 136. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 147. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 150. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 151. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 152. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 153. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 154. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 156. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 159. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 160. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 161. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 162. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 163. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 192. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 195. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 196. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 197. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 198. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 199. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 210. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 213. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 214. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 215. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 216. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 217. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 219. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 223. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 224. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 225. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 226. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 246. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 247. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 249. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 250. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 251. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 252. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 253. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 255. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 256. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 258. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 259. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 260. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 261. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 262. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 273. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 275. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 276. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 277. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 278. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 279. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 280. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 282. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 284. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 285. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 286. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 287. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 288. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 289. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MAR

Companies Mentioned

The companies profiled in this Endometrial Cancer Treatment market report include:
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • Eli Lilly and Company

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 9.38 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.24 Billion
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Endometrial Cancer Treatment - Global Strategic Business Report - Product Image

Endometrial Cancer Treatment - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Endometrial Cancer Treatment Market Report 2025 - Product Image

Endometrial Cancer Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Endometrial Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Endometrial Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 188 Pages
  • Global
From
Endometrial Cancer - Pipeline Insight, 2025 - Product Image

Endometrial Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • 180 Pages
  • Global
From
Uterine Cancer Therapeutics and Diagnostics - Global Strategic Business Report - Product Image

Uterine Cancer Therapeutics and Diagnostics - Global Strategic Business Report

  • Report
  • 173 Pages
  • Global
From

About the Endometrial Cancer Drug Market

The Endometrial Cancer Drug market is a subset of the Uterine Cancer Drugs market, which is composed of drugs used to treat endometrial cancer, a type of cancer that affects the lining of the uterus. Endometrial cancer drugs are typically used to reduce the size of tumors, reduce the spread of cancer cells, and reduce the risk of recurrence. Commonly used drugs include hormone therapy, chemotherapy, targeted therapy, and immunotherapy. Hormone therapy is used to reduce the amount of estrogen in the body, while chemotherapy is used to kill cancer cells. Targeted therapy is used to target specific cancer cells, while immunotherapy is used to boost the body's immune system to fight cancer. Some companies in the Endometrial Cancer Drug market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.